Cargando…

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

BACKGROUND: Prostate cancer screening with prostate-specific antigen (PSA) has shown to reduce prostate cancer mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC) trial. Overdetection and overtreatment are substantial unfavourable side effects with consequent healthca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heijnsdijk, E A M, der Kinderen, A, Wever, E M, Draisma, G, Roobol, M J, de Koning, H J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788248/ https://www.ncbi.nlm.nih.gov/pubmed/19904272 http://dx.doi.org/10.1038/sj.bjc.6605422

Ejemplares similares

Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam
por: Wever, Elisabeth M., et al.
Publicado: (2010)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual
por: Wever, E M, et al.
Publicado: (2012)

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
por: Getaneh, Abraham M., et al.
Publicado: (2020)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Overdetection of Breast Cancer
por: Yaffe, Martin J., et al.
Publicado: (2022)

Overdiagnosis and overtreatment of breast cancer: Microsimulation modelling estimates based on observed screen and clinical data
por: de Koning, Harry J, et al.
Publicado: (2006)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals
por: van Ravesteyn, N T, et al.
Publicado: (2011)

People’s willingness to accept overdetection in cancer screening: population survey
por: Van den Bruel, Ann, et al.
Publicado: (2015)

Overdiagnosis and overtreatment of early detected prostate cancer
por: Bangma, C. H., et al.
Publicado: (2007)

Ductal carcinoma in situ (DCIS): are we overdetecting it?
por: Evans, A
Publicado: (2004)

Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths
por: de Gelder, R, et al.
Publicado: (2011)

Cost‐effectiveness of multiparametric magnetic resonance imaging and MRI‐guided biopsy in a population‐based prostate cancer screening setting using a micro‐simulation model
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
por: Hogenhout, Renée, et al.
Publicado: (2022)

Overdetection in breast cancer screening: development and preliminary evaluation of a decision aid
por: Hersch, Jolyn, et al.
Publicado: (2014)

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis and overtreatment in service screening
por: Paci, Eugenio, et al.
Publicado: (2005)

Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer
por: Ferro, Matteo, et al.
Publicado: (2021)

Screening for prostate cancer: are organized screening programs necessary?
por: Roobol, Monique J.
Publicado: (2018)

Interpreting Overdiagnosis Estimates in Population-based Mammography Screening
por: de Gelder, Rianne, et al.
Publicado: (2011)

Women’s Acceptance of Overdetection in Breast Cancer Screening: Can We Assess Harm-Benefit Tradeoffs?
por: Stiggelbout, Anne, et al.
Publicado: (2019)

The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk
por: Melia, J, et al.
Publicado: (2006)

Prostate cancer screening and active surveillance in the Western world
por: Roobol, Monique J.
Publicado: (2018)

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?
por: Jegerlehner, Sabrina, et al.
Publicado: (2019)

Personalized strategies in population screening for prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2020)

Prostate cancer screening in Europe and Asia
por: Zhang, Kai, et al.
Publicado: (2017)

China county-based prostate specific antigen screening for prostate cancer and a cost-effective analysis
por: Zhang, Zhiguo, et al.
Publicado: (2021)

Ethnicity and prostate cancer: the way to solve the screening problem?
por: Bokhorst, Leonard P., et al.
Publicado: (2015)

Informing Women About Overdetection in Breast Cancer Screening: Two-Year Outcomes From a Randomized Trial
por: Hersch, Jolyn, et al.
Publicado: (2021)

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen
por: Jean-Pierre, Gannel
Publicado: (2017)

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer
por: Nyame, Yaw A, et al.
Publicado: (2020)

Reducing Cost of Care Through Deimplementation of Surgical Overtreatment
por: Nelson, Heidi
Publicado: (2021)

Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment
por: de Bekker-Grob, E W, et al.
Publicado: (2013)

Predicting biochemical recurrence and prostate cancer‐specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening‐ and clinically detected prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2019)

Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan
por: Masaoka, Hiroyuki, et al.
Publicado: (2017)

Potential diagnostic value of multiple indicators combined with total prostate-specific antigen in prostate cancer
por: Zhang, Qingxu, et al.
Publicado: (2023)

Brief report: Impact of healthcare quality on prostate specific antigen screening for the early detection of prostate cancer
por: Rezaee, Michael E., et al.
Publicado: (2019)

Overtreatment in the United States
por: Lyu, Heather, et al.
Publicado: (2017)

Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer
por: de Abreu, Darci Schiavon
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rp0308go95jnuos6a38bdragqi